Akero Therapeutics price target raised to $109 from $42 at UBS

UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” results from the 96-week biopsy data from the Phase 2b SYMMETRY trial of FGF21efruxifermin in metabolic dysfunction-associated steatohepatitis F4s, with efruxifermin 50mg resulting in a 24% effect size in fibrosis improvement over placebo at 96 weeks in a completers analysis, and in an ITT analysis, the effect size was 17%, the analyst tells investors in a research note. The firm still sees potential upside from here, and thinks the updated data is supportive of a significant opportunity for FGF21s as potentially the most potent anti-fibrotic class in MASH.